Background: Many low-risk acute coronary syndrome (ACS) patients are not pre-treated with a P2Y12 receptor inhibitor, and percutaneous coronary interventions (PCIs) are often performed on an ad hoc basis in this population. Pharmacodynamic (PD) studies comparing ticagrelor versus clopidogrel in patients undergoing ad hoc PCI are lacking.
Objectives: This study sought to assess PD effects of ticagrelor versus clopidogrel loading dose (LD) in the peri-procedural period among troponin-negative ACS patients undergoing ad hoc PCI.
Methods: This was a prospective, open-label, randomized, multicenter, parallel-group, phase IV PD study. One hundred P2Y12 inhibitor-naïve patients presenting with biomarker-negative ACS and undergoing ad hoc PCI, on a background of aspirin therapy, were randomized to receive either ticagrelor 180 mg LD or clopidogrel 600 mg LD. Platelet reactivity (P2Y12 reaction units [PRU]; VerifyNow assay) was measured at 5 time points: pre-LD, at 0.5, 2, and 8 h post-LD, and at end of PCI. The primary endpoint was PRU levels 2 h post-LD; secondary endpoints included PRU levels at all other time points and inhibition of platelet aggregation; an exploratory analysis evaluated rates of high on-treatment platelet reactivity (HPR) (PRU >208).
Results: At 2 h, PRU levels were significantly lower with ticagrelor versus clopidogrel (98.4 ± 95.4 vs. 257.5 ± 74.5; p < 0.001; primary endpoint). PRU levels diverged as early as 0.5 h post-LD, with significant differences observed by the end of PCI (mean 0.6 h post-LD) and maintained up to 8 h post-LD. HPR rates were also significantly reduced with ticagrelor compared with clopidogrel at the end of PCI (p = 0.030), and at 2 h (p < 0.001) and 8 h (p < 0.001) after LD.
Conclusions: In low-risk ACS patients undergoing ad hoc PCI, ticagrelor LD provides more prompt and potent platelet inhibition, and lower HPR rates, compared with clopidogrel LD. (Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients: NCT01603082).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2015.11.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.
BMC Med
December 2024
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Platelet-Function-Monitoring-Guided Therapy After Emergent Carotid Artery Stenting.
J Clin Med
November 2024
Cerebrovascular Research Unit Rigshospitalet, Department of Neurology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Antiplatelet therapy after emergent carotid stenting (eCAS) represents a challenge in balancing the risk of intracerebral hemorrhages (ICHs) and in-stent thrombosis (IST). Post-procedural platelet function monitoring may guide antiplatelet therapy and could potentially improve outcomes due to fewer post-procedural complications. Consecutive eCAS patients (2019-2021) were included in a single-center retrospective observational study.
View Article and Find Full Text PDFShort Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis.
Am J Cardiol
November 2024
Division of Cardiovascular Medicine, Baystate Medical Center, University of Massachusetts - Baystate, Springfield, Massachusetts.
The present guidelines recommend dual antiplatelet therapy (DAPT) for 6 to 12 months after percutaneous coronary intervention (PCI), with recent trials assessing the safety and efficacy of shortening DAPT duration to ≤3 months. A systematic search of PubMed, Scopus, and Cochrane Central databases identified studies comparing short DAPT, followed by P2Y12i monotherapy (78% ticagrelor) versus standard 12-month DAPT in patients who underwent PCI with a drug-eluting stent. A total of 9 randomized controlled trials, including 42,770 patients (short DAPT n = 21,370, 49.
View Article and Find Full Text PDFRandomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics.
Clin Transl Sci
November 2024
Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Article Synopsis
- Antiplatelet therapy, particularly with P2Y receptor inhibitors alongside aspirin, is essential for treating coronary artery disease, and different medication options can help tailor patient care.
- A study investigated the effects of a specific genetic mutation (G143E in CES1) on the effectiveness of clopidogrel and ticagrelor in inhibiting platelet aggregation in patients.
- Results showed that the G143E mutation significantly affected platelet response to clopidogrel, but not to ticagrelor, indicating ticagrelor may provide more consistent treatment for patients with clopidogrel response-altering genetics.
Ticagrelor versus Clopidogrel: Two Controversial Drugs in Patients with Acute Coronary Syndrome.
Cardiovasc Drugs Ther
November 2024
Department of Cardiology, Qingdao University, Qingdao, Shandong, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!